高级检索
    王勇, 刘会春, 金浩, 周磊, 庞青, 满忠然. 经皮胆道支架联合125Ⅰ粒子腔内置入治疗恶性梗阻性黄疸的疗效分析[J]. 蚌埠医科大学学报, 2019, 44(1): 37-40. DOI: 10.13898/j.cnki.issn.1000-2200.2019.01.011
    引用本文: 王勇, 刘会春, 金浩, 周磊, 庞青, 满忠然. 经皮胆道支架联合125Ⅰ粒子腔内置入治疗恶性梗阻性黄疸的疗效分析[J]. 蚌埠医科大学学报, 2019, 44(1): 37-40. DOI: 10.13898/j.cnki.issn.1000-2200.2019.01.011
    shu
    WANG Yong, LIU Hui-chun, JIN Hao, ZHOU Lei, PANG Qing, MAN Zhong-ran. Efficacy analysis of percutaneous biliary stent combined with 125Ⅰ intracavitary implantation in the treatment of malignant obstructive jaundice[J]. Journal of Bengbu Medical University, 2019, 44(1): 37-40. DOI: 10.13898/j.cnki.issn.1000-2200.2019.01.011
    Citation: WANG Yong, LIU Hui-chun, JIN Hao, ZHOU Lei, PANG Qing, MAN Zhong-ran. Efficacy analysis of percutaneous biliary stent combined with 125Ⅰ intracavitary implantation in the treatment of malignant obstructive jaundice[J]. Journal of Bengbu Medical University, 2019, 44(1): 37-40. DOI: 10.13898/j.cnki.issn.1000-2200.2019.01.011
    shu

    经皮胆道支架联合125Ⅰ粒子腔内置入治疗恶性梗阻性黄疸的疗效分析

    Efficacy analysis of percutaneous biliary stent combined with 125Ⅰ intracavitary implantation in the treatment of malignant obstructive jaundice

      摘要
    • 摘要:
      目的分析单纯经皮胆道支架置入术与联合125Ⅰ粒子腔内置入治疗恶性梗阻性黄疸的临床疗效差异。
      方法选择失去根治性手术机会或不愿行手术治疗的恶性梗阻性黄疸病人137例，施行经皮胆道支架置入术，据是否置入125Ⅰ粒子分为观察组(75例)和对照组(62例)，分析2组病人治疗前后肿瘤大小、肝功能、支架通畅情况及生存时间等的差异。
      结果与对照组相比，观察组病人术后3月肿瘤最大径和最小径均明显减小，肝功能各指标水平也明显改善(P < 0.01)。比较2组术后9、12、15个月支架通畅率观察组明显优于对照组(P < 0.01)。观察组1年生存率为72.0%，对照组1年生存率为33.9%，差异有统计学意义(P < 0.01)。
      结论经皮胆道支架联合125Ⅰ粒子腔内置入治疗在抑制肿瘤生长、改善肝功能、延长支架通畅及病人生存时间方面显著优于单纯经皮胆道支架置入术。

       

      Abstract:
      ObjectiveTo analyze the clinical efficacy of percutaneous biliary stent combined with 125Ⅰ intracavitary implantation in the treatment of malignant obstructive jaundice.
      MethodsA total of 137 malignant obstructive jaundice patients with inoperability were treated with percutaneous biliary stent implantation.According to the implantation of 125Ⅰ particle, the patients were divided into observation group(75 cases) and control group(62 cases).The tumor volume and liver function before and after treatment, stent patency time and survival time between two groups were analyzed and compared.
      ResultsCompared with the control group, the maximum and minimum diameter of tumor significantly decreased, and the liver function indexes were significantly improved in observation group at postoperative 3 months(P < 0.01).The stent patency rates in observation group at postoperative 9, 12 and 15 months were significantly better than those in control group(P < 0.01).The 1-year survival rate in observation group and control group was 72.0% and 33.9%, respectively, and the difference of which was statistically significant(P < 0.01).
      ConclusionsPercutaneous biliary stent combined with 125Ⅰ intracavitary implantation can inhibit the tumor growth, improve liver function and prolong the stent patency and survival time, and the treatment effect of which is superior to that of simple transcutaneous biliary stent implantation.

       

      • HTML全文
      • 参考文献(8)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回